Health·August 22, 2026·2 min read

DR Congo Launches Emergency Ebola Vaccine Trial

70,000 Doses Deployed as Deadly Outbreak Continues

The Democratic Republic of the Congo has begun deploying 70,000 doses of the Ervebo Ebola vaccine as part of an emergency response to the country's ongoing Ebola outbreak. The first shipment of 16,250 doses arrived at N'djili International Airport in Kinshasa, with additional deliveries expected over the coming days. Health officials, working alongside the World Health Organization (WHO) and the International Coordinating Group on Vaccine Provision, said the vaccine campaign is intended to help slow transmission while researchers evaluate whether the vaccine can provide protection against the Bundibugyo ebolavirus, a strain for which no licensed vaccine currently exists.

Under the emergency plan, 20,000 doses will be used in a Phase 3 clinical trial to study whether Ervebo, which is licensed against the Zaire ebolavirus, produces cross-protective immunity against the Bundibugyo strain. The remaining 50,000 doses will be used to vaccinate frontline healthcare workers and close contacts of confirmed Ebola patients using a ring-vaccination strategy that has helped contain previous outbreaks. The global vaccine alliance Gavi is providing $13 million to support vaccine procurement, transportation, cold-chain storage, and field operations.

Health Minister Samuel Roger Kamba said the remaining vaccine shipments are expected to arrive by August 24, allowing response teams to expand vaccination efforts across the affected provinces. Since the outbreak was declared on May 15, 2026, health authorities have reported 5,290 confirmed cases and 2,516 deaths, making it the country's largest recorded Ebola outbreak. WHO Director-General Tedros Adhanom Ghebreyesus said laboratory studies suggest Ervebo may provide some cross-protection, but clinical data are needed before health officials can determine how effective the vaccine will be against the Bundibugyo strain.

Aid organizations, including Médecins Sans Frontières (MSF), have warned that insecurity, difficult terrain, and limited healthcare infrastructure continue to complicate contact tracing and treatment efforts. Officials hope the emergency vaccination campaign will reduce transmission while researchers gather data that could improve future responses to outbreaks caused by less common Ebola variants.

Community discussion
"Should experimental vaccines be deployed during major outbreaks before their effectiveness against a specific virus strain has been fully established?"